Katleen Vandamme

Prof. Katleen Vandamme

Department of Oral Health Sciences, KU Leuven, 3000 Leuven, Belgium
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2018 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
CMCarlos Marin
Carlos Marin
FLFrank P. Luyten
Frank P. Luyten
BSBart Van der Schueren
Bart Van der Schueren
GKGreet Kerckhofs
Greet Kerckhofs
Katleen VandammeKatleen Vandamme
Katleen Vandamme
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease known by the presence of elevated blood glucose levels. Nowadays, it is perceived as a worldwide epidemic, with a very high socioeconomic impact on public health. Many are the complications caused by this chronic disorder, including a negative impact on the cardiovascular system, kidneys, eyes, muscle, blood vessels, and nervous system. Recently, there has been increasing evidence suggesting that T2DM also adversely affects the skeletal system, causing detrimental bone effects such as bone quality deterioration, loss of bone strength, increased fracture risk, and impaired bone healing. Nevertheless, the precise mechanisms by which T2DM causes detrimental effects on bone tissue are still elusive and remain poorly studied. The aim of this review was to synthesize current knowledge on the different factors influencing the impairment of bone fracture healing under T2DM conditions. Here, we discuss new approaches used in recent studies to unveil the mechanisms and fill the existing gaps in the scientific understanding of the relationship between T2DM, bone tissue, and bone fracture healing.

12 October 2012 in Clinical Oral Implants Research
Verified
Journal Article
Closed access
PDF file
INIgnace Naert
Ignace Naert
JDJoke Duyck
Joke Duyck
Katleen VandammeKatleen Vandamme
Katleen Vandamme

13 February 2007 in European Journal of Oral Sciences
Verified
Journal Article
Closed access
PDF file
Katleen VandammeKatleen Vandamme
Katleen Vandamme
INIgnace Naert
Ignace Naert
LGLiesbet Geris
Liesbet Geris
JSJozef Vander Sloten
Jozef Vander Sloten
RPRobert Puers
Robert Puers
JDJoke Duyck
Joke Duyck

1 October 2012 in Tissue Engineering Part A
Verified
Journal Article
Closed access
PBPierre Becquart
Pierre Becquart
ACAdeline Cambon-Binder
Adeline Cambon-Binder
LMLaurent-Emmanuel Monfoulet
Laurent-Emmanuel Monfoulet
MBMarianne Bourguignon
Marianne Bourguignon
Katleen VandammeKatleen Vandamme
Katleen Vandamme
DLDelphine Logeart-Avramoglou
Delphine Logeart-Avramoglou
Local tissue ischemia is a prime cause responsible for the massive cell death in tissue-engineered (TE) constructs observed postimplantation. To assess the impact of ischemia on the death of implanted human multipotent stromal cells (hMSCs), which have great potential for repairing damaged tissues, we hereby investigated the in vivo temporal and spatial fate of human Luc-GFP-labeled MSCs within fibrin gel/coral scaffolds subcutaneously implanted in nude mice. In vivo bioluminescence imaging monitoring and histological analyses of the constructs tested confirmed the irremediable death of hMSCs over 30 days postimplantation. The kinetics of expression of three hypoxic/ischemic markers (HIF-1α, LDH-A, and BNIP3) was also monitored. Our results provided evidence that hMSCs located within the core of implanted constructs died faster and predominantly and strongly expressed the aforementioned ischemic markers. In contrast, cells located in the outer regions of TE constructs were reperfused by neovascularization and were still viable (as evidenced by their ex-vivo proliferative potential) at day 15 postimplantation. These results support the explanation that in the central part of the constructs tested, death of hMSCs was due to ischemia, whereas in the periphery of these constructs, cell death was due to another mechanism that needs to be elucidated.

27 November 2013 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
NDNicolas Delattin
Nicolas Delattin
KBKatrijn De Brucker
Katrijn De Brucker
Katleen VandammeKatleen Vandamme
Katleen Vandamme
EMEls Meert
Els Meert
AMArnaud Marchand
Arnaud Marchand
KTKarin Thevissen
Karin Thevissen
Biofilms of Candida species, often formed on medical devices, are generally resistant to currently available antifungal drugs. The aim of this study was to identify compounds that increase the activity of amphotericin B and caspofungin, commonly used antifungal agents, against Candida biofilms. A library containing off-patent drugs was screened for compounds, termed enhancers, that increase the in vitro activity of amphotericin B against Candida albicans biofilms. Biofilms were grown in 96-well plates and growth was determined by the cell titre blue assay. Synergy between identified enhancers and antifungal agents was further characterized in vitro using fractional inhibitory concentration index (FICI) values and in vivo using a worm biofilm infection model. In light of the application of these enhancers onto implants, their possible effect on the growth potential of MG63 osteoblast-like cells was assessed. Pre-incubation of C. albicans biofilms with subinhibitory concentrations of the enhancers drospirenone, perhexiline maleate or toremifene citrate significantly increased the activity of amphotericin B or caspofungin (FICI < 0.5) against C. albicans and Candida glabrata biofilms. Moreover, these enhancers did not affect the growth potential of osteoblasts. Interestingly, toremifene citrate also enhanced the in vitro activity of caspofungin in a mixed biofilm consisting of C. albicans and Staphylococcus epidermidis. Furthermore, we demonstrate synergy between toremifene citrate and caspofungin in an in vivo worm C. albicans biofilm infection model. Our data demonstrate an in vitro and in vivo enhancement of the antibiofilm activity of caspofungin by toremifene citrate. Furthermore, our results pave the way for implant-related applications of the identified enhancers.

7 July 2010 in Clinical Oral Implants Research
Verified
Journal Article
Closed access
PDF file
JDJoke Duyck
Joke Duyck
LCLivía Corpas
Livía Corpas
SVStephanie Vermeiren
Stephanie Vermeiren
TOToru Ogawa
Toru Ogawa
MQMarc Quirynen
Marc Quirynen
INIgnace Naert
Ignace Naert